Ben Woodington

Ben Woodington is the CEO and co-founder of Opto Biosystems, a bioelectronics start-up focused on developing minimally invasive neural interfaces aimed at treating neurological diseases. He has been in this role since May 2022, leading the company's mission to innovate in the field of neurotechnology and improve treatment options for challenging medical conditions such as brain cancer and epilepsy.123

Education and Background

Woodington completed his PhD in Bioelectronics at the University of Cambridge, where he specialized in developing flexible and shape-adaptive neural interfaces for sensing and stimulating the central nervous system.13 His academic journey also includes a Master of Research in Sensor Technologies and Applications and a Bachelor of Science in Chemistry from the University of Surrey.13

Before founding Opto Biosystems, he worked in various engineering and scientific roles, including positions at Vectura Group plc, where he contributed to the development and commercialization of medical devices.13 His experience in medical device engineering and bioelectronics research has been pivotal in translating his academic work into practical applications in healthcare.

Vision and Impact

Woodington's work at Opto aims to revolutionize how neurological diseases are treated by creating implantable, miniaturized sensors that can provide real-time monitoring of brain activity without the need for major surgery.23 The technology is designed to be less invasive, potentially allowing for outpatient procedures and improving patient outcomes in the treatment of serious conditions.23

Under his leadership, Opto Biosystems has garnered attention and funding, including £1.85 million in pre-seed funding to further develop its innovative technologies.24 Woodington's commitment to advancing bioelectronics reflects his belief in the transformative potential of technology in medicine, particularly in providing better tools for clinicians and improving patient care.3